The NMPA approved T-DXd after neoadjuvant therapy, based on DESTINY-Breast05 data, in which the agent lowered the risk of recurrence or death vs T-DM1.
Related to this article
Check out this September recap of OncLive’s coverage of the top news and expert insights in breast cancer.
The FDA approved tucatinib plus trastuzumab and pertuzumab as maintenance for advanced HER2-positive breast cancer after induction.
Experts spotlight the variety of breast cancer research being presented at the 2026 ESMO Congress.
Advertisement
Advertisement
Trending on OncLive
1
VIR-5500 Receives FDA Fast Track Designation in mCRPC
2
New Statewide Plan Aims to Eliminate Cervical Cancer in Texas by 2032
3
China’s NMPA Approves Adjuvant T-DXd for HER2+ Early Breast Cancer With Residual Invasive Disease
4
Iberdomide Plus Daratumumab/Dexamethasone Yields Significant PFS Benefit in R/R Myeloma
5